217. Deputy Barry Heneghan asked the Minister for Health whether the free HRT scheme will be extended to cover hormone replacement therapy for patients with congenital or permanent endocrine conditions, including testosterone replacement for Klinefelter syndrome. [74737/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Barry Heneghan under the heading Medicinal Products.
26 questions match, newest first.
218. Deputy Barry Heneghan asked the Minister for Health the current status of the HSE's assessment of dupilumab for eosinophilic oesophagitis; and the expected date of a decision. [74736/26]
219. Deputy Barry Heneghan asked the Minister for Health the action the HSE and HPRA are taking on the current supply shortage of budesonide orodispersible tablets in the State. [74735/26]
220. Deputy Barry Heneghan asked the Minister for Health the current status of the HSE's full health technology assessment of budesonide orodispersible tablets (Jorveza, NCPE HTA ID 24014) for eosinophilic oesophagitis, commissioned on 25 June 2024; the reason no outcome has been published in over two years; and the expected date of a reimbursement decision. [74734/26]
791. Deputy Barry Heneghan asked the Minister for Health whether she is aware of delays in accessing a drug (details supplied) for Friedreich’s ataxia due to capacity constraints at the Combined Ataxia Clinic, Tallaght University Hospital; the timeframe for all eligible patients to commence treatment; whether additional resources will be provided; the current clinic waiting times; and measures to ensure timely specia…
755. Deputy Barry Heneghan asked the Minister for Health whether the reimbursement arrangements under the community drugs schemes will be reviewed to ensure that patients are not financially disadvantaged when unlicensed medicines must be supplied as a result of shortages of licensed products; and if she will make a statement on the matter. [52900/26]
756. Deputy Barry Heneghan asked the Minister for Health whether her Department has assessed the financial impact of medicine shortages on residents of private nursing homes supported under the fair deal scheme, particularly where unlicensed medicines attract additional costs that are not fully covered under existing reimbursement arrangements; and if she will make a statement on the matter. [52901/26]
757. Deputy Barry Heneghan asked the Minister for Health the measures that are being taken by her Department and the HSE to minimise the impact of shortages of essential medicines, including medicines used in the treatment of heart failure and cardiovascular disease, and to ensure continuity of treatment for patients; and if she will make a statement on the matter. [52902/26]
758. Deputy Barry Heneghan asked the Minister for Health whether guidance has been issued to the HSE and community pharmacies regarding the reimbursement of unlicensed medicines supplied in place of licensed medicines that are unavailable due to national shortages; and if she will make a statement on the matter. [52903/26]
759. Deputy Barry Heneghan asked the Minister for Health the number and name of medicines currently subject to national shortages for which pharmacies are routinely sourcing unlicensed alternatives, in tabular form; whether her Department has assessed the additional costs incurred by medical card patients as a consequence; and if she will make a statement on the matter. [52904/26]
818. Deputy Barry Heneghan asked the Minister for Health the current status of the health technology assessment and reimbursement process for the medicine belzutifan for the treatment of eligible patients with Von Hippel-Lindau (VHL) syndrome; the expected timelines for completion of the assessment and any subsequent reimbursement decision; and if she will make a statement on the matter. [51420/26]
819. Deputy Barry Heneghan asked the Minister for Health the steps her Department and the HSE are taking to facilitate timely access to belzutifan for eligible patients with Von Hippel-Lindau (VHL) syndrome, if approved for reimbursement; whether engagement has taken place, or is planned, with clinicians, patient representative organisations and other relevant stakeholders regarding access to this treatment; and if s…
286. Deputy Barry Heneghan asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy (SMA) (details supplied); when an outcome from the HSE drugs group is expected; and if she will make a statement on the matter. [38237/26]
1133. Deputy Barry Heneghan asked the Minister for Health whether her Department has examined the practice of pharmacies charging additional fees for dispensing medications in blister packs where this is clinically required, particularly for older persons with complex medication regimes; whether any guidance or regulation exists governing such charges under the community drug schemes; if consideration is being given …
943. Deputy Barry Heneghan asked the Minister for Health when Skyclarys (omaveloxolone), the first approved treatment for Friedreich’s ataxia, will be made available to patients in Ireland through reimbursement; if she will prioritise the assessment and reimbursement process given the urgent clinical need for the approximately 200 people living with this progressive condition; and if she will make a statement on the …
931. Deputy Barry Heneghan asked the Minister for Health the reasons for the introduction of a charge for blister packaging by pharmacists from January 2026; if she acknowledges that many of the people who rely on this service live with serious medical conditions and have very limited income; and if she will make a statement on the matter. [66130/25]
932. Deputy Barry Heneghan asked the Minister for Health if she will consider introducing financial supports or exemptions for patients who rely on blister packaging because of complex medical conditions, cognitive difficulties or disability, given that any additional charge would disproportionately impact those on low incomes; and if she will make a statement on the matter. [66131/25]
933. Deputy Barry Heneghan asked the Minister for Health if she will engage with the pharmacy sector to ensure that any changes to blister packaging provision do not reduce medication safety for vulnerable patients who depend on organised dosing systems; and if she will make a statement on the matter. [66132/25]
934. Deputy Barry Heneghan asked the Minister for Health if her Department carried out any assessment of the financial or clinical impact of introducing a blister pack charge, particularly for older people and people with disabilities; and if she will make a statement on the matter. [66133/25]
651. Deputy Barry Heneghan asked the Minister for Health if she will examine the current regulatory status of naloxone and consider allowing approved formulations to be made available over-the-counter in order to improve timely access to this emergency medication, in line with international practice; and if she will make a statement on the matter. [64949/25]
652. Deputy Barry Heneghan asked the Minister for Health the current supply pathways through which community and voluntary organisations can access and distribute naloxone; if consideration is being given to expanding these pathways to reduce delays; and if she will make a statement on the matter. [64953/25]
2649. Deputy Barry Heneghan asked the Minister for Health the plans in place for the assessment and potential inclusion of the psychiatric medication lumateperone for the treatment of bipolar disorder under the drug payment scheme; and if she will make a statement on the matter. [41240/25]
423. Deputy Barry Heneghan asked the Minister for Health the steps she is taking to ensure that a drug (details supplied) will be assessed and made available as quickly as possible following its recent EU approval, given how important early access is for children with Duchenne muscular dystrophy; and if she will make a statement on the matter. [33451/25]
1523. Deputy Barry Heneghan asked the Minister for Health if work has begun to explore early access schemes for certain medicines, as outlined in the Programme for Government; the person in her Department that will have responsibility for this work; if this will include a review of early access schemes already operating in other European countries; and if she will make a statement on the matter. [30015/25]
2182. Deputy Barry Heneghan asked the Minister for Health if she will examine the cost of the anti-sickness medication cariban for pregnant women (details supplied); and if she will make a statement on the matter. [19605/25]